Emicizumab is a humanized, monoclonal bi-specifc antibody mimicking FVIII function by bridging together FIXa and FX; it has been initially introduced for prophylaxis in patients affected by haemophilia with inhibitors [15]. Here, F8 is linked to hemophilia.